Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.
about
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer.Translational research and application of basic biology to clinical trial development in GI cancers.Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
P2860
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Safety and antitumor activity ...... advanced colorectal carcinoma.
@en
Safety and antitumor activity ...... advanced colorectal carcinoma.
@nl
type
label
Safety and antitumor activity ...... advanced colorectal carcinoma.
@en
Safety and antitumor activity ...... advanced colorectal carcinoma.
@nl
prefLabel
Safety and antitumor activity ...... advanced colorectal carcinoma.
@en
Safety and antitumor activity ...... advanced colorectal carcinoma.
@nl
P2093
P2860
P50
P1433
P1476
Safety and antitumor activity ...... advanced colorectal carcinoma
@en
P2093
Albiruni R Abdul Razak
Carlos Gomez-Roca
Elena Elez
John M Wallmark
Judith Raimbourg
Karen Stein
Katia Dotti
Mark N Stein
Marlena Gould
Roger B Cohen
P2860
P304
P356
10.1371/JOURNAL.PONE.0189848
P407
P577
2017-12-28T00:00:00Z